Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

May

Today In Oncology

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

Promising Signal Only ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

AI Pathology Framework for Biological Understanding of Tumors

AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans

Breast Density Reduction: Endoxifen vs Tamoxifen